Through the 3rd allocation to third parties, 2,932,000 ordinary shares are allocated at 140 yen per share to raise approximately 410.48 million yen. The total number of stock acquisition rights is 29,320 rights with an exercise period from 2026\/9\/4 to 2030\/9\/3. Use of funds includes research and development and initiation of clinical trials for the GPC-1 CAR-T therapy targeting refractory solid tumors.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4978","jir_company_name":"\u682a\u5f0f\u4f1a\u793e\u30ea\u30d7\u30ed\u30bb\u30eb","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4978-20260819-01.pdf","jir_short_summary":"Through the 3rd allocation to third parties, 2,932,000 ordinary shares are allocated at 140 yen per share to raise approximately 410.48 million yen. The total number of stock acquisition rights is 29,320 rights with an exercise period from 2026\/9\/4 to 2030\/9\/3. Use of funds includes research and development and initiation of clinical trials for the GPC-1 CAR-T therapy targeting refractory solid tumors.","jir_summary":"### Overview of financing and issuance\nAs the 3rd allocation to third parties, 2,932,000 ordinary shares will be allocated, with a payment amount of 140 yen per share, raising a total of 41,048,0000 yen. The payment amount for 29,320 stock acquisition rights is also the same, with an exercise period from 2026\/9\/4 to 2030\/9\/3. The recipient is CVI Investments, Inc., and the total funds are 9,599,368,00 yen (aggregate of the payment amounts and stock acquisition rights). Use of funds includes research and development and initiation preparation costs for GPC-1 CAR-T therapy, as well as working capital, etc.\n\n### Use of funds and rationale\nThe specific use of funds consists of: (1) R&D and initiation preparation costs for GPC-1 CAR-T therapy targeting refractory solid tumors, and (2) working capital, etc. The GPC-1 CAR-T therapy is being developed under a joint research project with Kyoto University Graduate School of Medicine and International University of Health and Welfare, establishing non-clinical trials, quality, and manufacturing methods to prepare for clinical trials. The rationality of the use of funds is expected to contribute to mid- to long-term corporate value enhancement.","jir_financial_highlights":"Issued number of new shares: 2,932,000 shares (Unknown)\nIssue price: 140 yen (Unknown)\nAmount of funds raised: 410,480,000 yen (Unknown)\nTotal number of stock acquisition rights: 29,320 rights (Unknown)\nExercise period: From September 4, 2026 to September 3, 2030 (Unknown)","jir_category":"","jir_hashtags":"#Riprocell, #CapitalPolicy_ThirdPartyAllocation, #StockAcquisitionRights","jir_key_figures":"Issued ordinary shares: 2,932,000 shares (3rd allocation to third parties)\nPayment amount: 140 yen\/share\nAmount of funds raised: 410,480,000 yen\nTotal number of stock acquisition rights: 29,320 rights\nExercise period: 2026\/9\/4 to 2030\/9\/3","jir_meta_title":"Riprocell announces financing through third-party allocation of shares and stock acquisition rights | August 19, 2026","jir_meta_description":"Riprocell announces third-party allocation of 2,932,000 shares and the issuance of stock acquisition rights. Payment amount is 140 yen per share; use of funds includes CAR-T therapy research and development for refractory solid tumors and pre-clinical\/operating funds. Details of future capital policy and fund utilization.","jir_og_title":"Riprocell announces financing through third-party allocation of shares and stock acquisition rights | August 19, 2026","jir_og_description":"Riprocell issues 2,932,000 shares via third-party allocation with a payment of 140 yen. Funds will support CAR-T therapy R&D and working capital. Stock acquisition rights also issued, exercisable until 2030.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58459,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-105373","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n